6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis

European Respiratory Journal

Volumn 43, Issue 5, 2014, Pages 1421-1429

  Du Bois, Roland M ^a   Albera, Carlo ^b   Bradford, Williamson Z ^c   Costabel, Ulrich ^d   Leff, Jonathan A ^c   Noble, Paul W ^e   Sahn, Steven A ^f   Valeyre, Dominique ^g   Weycker, Derek ^h   King Jr , Talmadge E ⁱ  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

^c InterMune Inc   (United States)

^d RUHRLANDKLINIK   (Germany)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h POLICY ANALYSIS INC PAI   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON 1B; UNCLASSIFIED DRUG;

6 MINUTE WALK DISTANCE; AGE; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL RISK PREDICTION MODEL; CONTROLLED STUDY; EXERCISE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEASUREMENT ACCURACY; MORTALITY; NONBIOLOGICAL MODEL; OUTCOME ASSESSMENT; OXYGEN THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TREATMENT DURATION; BIOLOGICAL MODEL; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); DOUBLE BLIND PROCEDURE; EXERCISE TEST; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VITAL CAPACITY; WALKING;

AGED; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; VITAL CAPACITY; WALKING;

EID: 84899830690     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00131813     Document Type: Article

References (39)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-440.
3. Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007; 176: 277-284.
4. SEER cancer statistics review. Statistics based on Surveillance Epidemiology and End Results (SEER) Program 18 data (2003 to 2009) http://seer.cancer.gov Date last updated: April 15, 2009. Date last accessed: March 4, 2014.
5. King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-1181.
6. Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 639-644.
7. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 459-466.
8. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691.
9. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167: 962-969.
10. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 531-537.
11. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-542.
12. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543-548.
13. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830-836.
14. Hook JL, Arcasoy SM, Zemmel D, et al. Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. Eur Respir J 2012; 39: 359-365.
15. Mura M, Porretta MA, Bargagli E, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 2012; 40: 101-109.
16. Maldonado F, Moua T, Rajagopalan S, et al. Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis. Eur Respir J 2014; 43: 204-212.
17. Lipkin DP, Scriven AJ, Crake T, et al. Six-minute walking test for assessing exercise capacity in chronic heart failure. Br Med J (Clin Res Ed) 1986; 292: 653-655.
18. Cahalin LP, Mathier MA, Semigran MJ, et al. The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest 1996; 110: 325-332.
19. Gomberg-Maitland M, Huo D, Benza RL, et al. Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. J Heart Lung Transplant 2007; 26: 732-738.
20. Guyatt GH, Pugsley SO, Sullivan MJ, et al. Effect of encouragement on walking test performance. Thorax 1984; 39: 818-822.
21. Bernstein ML, Despars JA, Singh NP, et al. Reanalysis of the 12-minute walk in patients with chronic obstructive pulmonary disease. Chest 1994; 105: 163-167.
22. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132: 207-213.
23. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183: 1231-1237.
24. Caminati A, Bianchi A, Cassandro R, et al. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 2009; 103: 117-123.
25. Lederer DJ, Arcasoy SM, Wilt JS, et al. Six-minute walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 659-664.
26. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon c-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-228.
27. American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161: 646-664.
28. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
29. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172.
30. Allison PD. Survival analysis using the SAS System: a practical guide. Cary, SAS Institute Inc., 1995; p. 292.
31. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389.
32. American Thoracic Society. ATS Statement. Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
33. Eaton T, Young P, Milne D, et al. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 1150-1157.
34. Solway S, Brooks D, Lacasse Y, et al. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 2001; 119: 256-270.
35. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743-753.
36. Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009; 373: 739-745.
37. Butler J, Kalogeropoulos A, Georgiopoulou V, et al. Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail 2008; 1: 125-133.
38. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003; 290: 1049-1056.
39. Rathore SS, Weinfurt KP, Foody JM, et al. Performance of the Thrombolysis in Myocardial Infarction (TIMI) STelevation myocardial infarction risk score in a national cohort of elderly patients. Am Heart J 2005; 150: 402-410.